Mycenax Biotech Inc. - Laporan Laba Rugi (TTM)

Mycenax Biotech Inc.
TW ˙ TPEX
NT$ 50.80 ↓ -0.70 (-1.36%)
2024-10-25
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Mycenax Biotech Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 619 665 888 725 732 774 708 752 757 732 645 712 666 653 594 577 673 684 725 727
Change (%) 7.55 33.42 -18.28 0.84 5.84 -8.61 6.34 0.64 -3.30 -11.90 10.30 -6.46 -1.95 -8.92 -2.93 16.62 1.65 6.07 0.27
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 414 479 543 536 583 637 657 729 786 846 942 1,047 1,029 1,028 952 893 956 925 959 953
Change (%) 15.57 13.43 -1.34 8.74 9.27 3.27 10.95 7.77 7.62 11.30 11.20 -1.76 -0.08 -7.37 -6.20 7.05 -3.22 3.60 -0.62
% of Revenue 66.97 71.96 61.18 73.86 79.64 82.23 92.91 96.94 103.80 115.52 145.95 147.14 154.54 157.49 160.17 154.78 142.09 135.29 132.14 130.97
Gross Operating Profit 204 187 345 190 149 138 50 23 -29 -114 -296 -335 -363 -375 -358 -316 -283 -241 -233 -225
Change (%) -8.71 84.74 -44.97 -21.46 -7.59 -63.56 -54.03 -224.73 295.30 160.77 13.15 8.23 3.35 -4.67 -11.63 -10.40 -14.78 -3.40 -3.38
% of Revenue 33.03 28.04 38.82 26.14 20.36 17.77 7.09 3.06 -3.80 -15.52 -45.95 -47.14 -54.54 -57.49 -60.17 -54.78 -42.09 -35.29 -32.14 -30.97
SG&A 97 105 116 104 111 127 131 149 138 187 190 218 214 151 148 121 138 142 139 137
Change (%) 7.76 11.08 -10.57 7.18 13.84 3.59 13.80 -7.39 35.30 1.52 14.42 -1.53 -29.47 -1.77 -18.41 14.36 2.52 -2.08 -1.39
% of Revenue 15.70 15.73 13.09 14.33 15.23 16.38 18.56 19.87 18.28 25.58 29.48 30.58 32.19 23.15 24.97 20.99 20.58 20.76 19.17 18.85
R&D 105 47 52 57 77 96 103 116 126 144 139 126 106 76 67 67 71 78 82 82
Change (%) -55.53 12.63 7.91 35.87 25.18 6.98 12.72 9.03 13.93 -3.67 -8.91 -15.87 -28.68 -11.03 -0.54 6.29 9.65 4.54 0.30
% of Revenue 16.90 6.99 5.90 7.79 10.50 12.42 14.53 15.41 16.69 19.66 21.50 17.76 15.97 11.62 11.35 11.63 10.60 11.43 11.27 11.27
OpEx 616 630 712 696 771 860 892 995 1,081 1,177 1,270 1,391 1,319 1,255 1,168 1,081 1,166 1,145 1,179 1,172
Change (%) 2.27 12.98 -2.16 10.71 11.51 3.73 11.57 8.61 8.95 7.91 9.48 -5.13 -4.91 -6.91 -7.42 7.82 -1.75 2.96 -0.64
% of Revenue 99.57 94.68 80.17 95.98 105.37 111.02 126.01 132.21 142.68 160.77 196.93 195.47 198.25 192.26 196.49 187.40 173.27 167.48 162.57 161.09
Operating Income 3 35 176 29 -39 -85 -184 -242 -323 -445 -625 -679 -654 -602 -574 -504 -493 -462 -454 -444
Change (%) 1,235.77 397.20 -83.43 -234.67 117.28 115.70 31.68 33.37 37.67 40.52 8.64 -3.74 -7.92 -4.74 -12.08 -2.23 -6.39 -1.65 -2.10
% of Revenue 0.43 5.32 19.83 4.02 -5.37 -11.02 -26.01 -32.21 -42.68 -60.77 -96.93 -95.47 -98.25 -92.26 -96.49 -87.40 -73.27 -67.48 -62.57 -61.09
Interest Expense -2 -1 -1 -0 -0 -1 -2 -3 -8 -15 -21 -25 -25 -23 -22 -24 -25 -26 -28 -28
Change (%) -58.19 -9.94 -49.94 -58.97 633.12 37.25 107.39 147.35 86.66 34.08 19.12 2.68 -7.21 -4.11 6.55 4.06 4.89 5.33 0.04
% of Revenue -0.33 -0.13 -0.09 -0.05 -0.02 -0.15 -0.23 -0.44 -1.09 -2.11 -3.20 -3.46 -3.80 -3.59 -3.78 -4.15 -3.71 -3.82 -3.80 -3.79
Net Income 1 31 167 19 -46 -90 -186 -233 -327 -454 -713 -764 -713 -683 -577 -512 -536 -467 -461 -496
Change (%) 4,574.92 439.41 -88.51 -341.50 93.93 106.92 25.46 40.19 38.72 57.16 7.15 -6.67 -4.21 -15.43 -11.39 4.81 -12.90 -1.39 7.72
% of Revenue 0.11 4.65 18.81 2.64 -6.33 -11.61 -26.28 -31.00 -43.18 -61.95 -110.51 -107.35 -107.11 -104.63 -97.15 -88.69 -79.71 -68.30 -63.50 -68.22

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista